June 22, 2016June 22, 2016

INOpulse Devices for PAH Disorders Evaluated in Clinical Trials

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Bellerophon Therapeutics recently enrolled the first participants in the Phase 3 INOvation-1 clinical trial intended to test the efficiency and safety of INOpulse for the treatment of pulmonary arterial hypertension (PAH). ... Read more

January 26, 2016January 26, 2016

New Respiratory Therapy’s Clinical Program Getting European Patent Protection

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company specializing in the development of drugs and devices for cardiopulmonary conditions, recently announced that the European Patent Office has issued a Notice of Intention ... Read more